CRISPR Therapeutics AG
CRSP56.250USD
-0.430-0.76%
Close 12/15, 16:00（ET）Quotes delayed by 15 min
5.28BMarket Cap
LossP/E TTM
More Details of CRISPR Therapeutics AG Company
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
CRISPR Therapeutics AG Info
Ticker SymbolCRSP
Company nameCRISPR Therapeutics AG
IPO dateOct 19, 2016
CEOKulkarni (Samarth)
Number of employees393
Security typeOrdinary Share
Fiscal year-endOct 19
AddressBaarerstrasse 14
CityZUG
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountrySwitzerland
Postal codeCH-6300
Phone41415613279
Websitehttps://crisprtx.com/
Ticker SymbolCRSP
IPO dateOct 19, 2016
CEOKulkarni (Samarth)
Company Executives of CRISPR Therapeutics AG
Name
Name/Position
Position
Shareholding
Change
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
339.82K
+18.56%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Dr. Briggs W. Morrison, M.D.
Dr. Briggs W. Morrison, M.D.
Director
Director
--
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Sandesh Mahatme
Mr. Sandesh Mahatme
Independent Director
Independent Director
--
--
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
--
--
Dr. Maria Fardis, Ph.D.
Dr. Maria Fardis, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
339.82K
+18.56%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Dr. Briggs W. Morrison, M.D.
Dr. Briggs W. Morrison, M.D.
Director
Director
--
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
10.27%
BlackRock Institutional Trust Company, N.A.
6.56%
Capital International Investors
5.93%
Orbis Investment Management Ltd.
5.23%
State Street Investment Management (US)
4.20%
Other
67.81%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
10.27%
BlackRock Institutional Trust Company, N.A.
6.56%
Capital International Investors
5.93%
Orbis Investment Management Ltd.
5.23%
State Street Investment Management (US)
4.20%
Other
67.81%
Shareholder Types
Shareholders
Proportion
Investment Advisor
43.79%
Investment Advisor/Hedge Fund
23.62%
Venture Capital
3.41%
Research Firm
3.14%
Hedge Fund
2.56%
Individual Investor
1.61%
Bank and Trust
0.52%
Pension Fund
0.44%
Sovereign Wealth Fund
0.43%
Other
20.49%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
980
79.52M
84.90%
+75.16K
2025Q3
1019
79.46M
89.59%
+5.57M
2025Q2
986
73.90M
82.20%
+7.69M
2025Q1
943
66.36M
83.61%
-5.70M
2024Q4
951
66.15M
80.53%
+2.60M
2024Q3
955
62.43M
76.50%
+840.55K
2024Q2
969
61.63M
76.06%
+573.40K
2024Q1
979
61.11M
68.18%
+3.34M
2023Q4
980
54.61M
75.07%
+613.05K
2023Q3
983
54.08M
76.54%
+343.99K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
10.18M
11.2%
+17.19K
+0.17%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.42M
5.96%
+3.00M
+124.40%
Jun 30, 2025
Capital International Investors
5.59M
6.15%
-479.37K
-7.89%
Jun 30, 2025
Orbis Investment Management Ltd.
2.76M
3.04%
+1.20M
+76.88%
Jun 30, 2025
State Street Investment Management (US)
3.27M
3.6%
+859.33K
+35.64%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
3.68M
4.05%
-115.08K
-3.03%
Jun 30, 2025
The Vanguard Group, Inc.
2.28M
2.51%
+528.38K
+30.18%
Jun 30, 2025
UBS Financial Services, Inc.
2.59M
2.85%
+859.43K
+49.73%
Jun 30, 2025
Amova Asset Management Co., Ltd.
2.41M
2.66%
-125.05K
-4.92%
Jun 30, 2025
Amova Asset Management Americas, Inc
2.41M
2.65%
-125.62K
-4.95%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
10.33%
Global X Genomics & Biotechnology ETF
5.71%
ARK Innovation ETF
5.12%
AXS Green Alpha ETF
4.84%
WisdomTree BioRevolution Fund
2.81%
Virtus LifeSci Biotech Products ETF
2.48%
State Street SPDR S&P Biotech ETF
2.41%
Direxion Daily S&P Biotech Bull 3X Shares
1.48%
Franklin Genomic Advancements ETF
0.92%
ProShares Ultra Nasdaq Biotechnology
0.59%
View more
ARK Genomic Revolution ETF
Proportion10.33%
Global X Genomics & Biotechnology ETF
Proportion5.71%
ARK Innovation ETF
Proportion5.12%
AXS Green Alpha ETF
Proportion4.84%
WisdomTree BioRevolution Fund
Proportion2.81%
Virtus LifeSci Biotech Products ETF
Proportion2.48%
State Street SPDR S&P Biotech ETF
Proportion2.41%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.48%
Franklin Genomic Advancements ETF
Proportion0.92%
ProShares Ultra Nasdaq Biotechnology
Proportion0.59%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of CRISPR Therapeutics AG?
The top five shareholders of CRISPR Therapeutics AG are:
ARK Investment Management LLC holds 10.18M shares, accounting for 11.20% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.42M shares, accounting for 5.96% of the total shares.
Capital International Investors holds 5.59M shares, accounting for 6.15% of the total shares.
Orbis Investment Management Ltd. holds 2.76M shares, accounting for 3.04% of the total shares.
State Street Investment Management (US) holds 3.27M shares, accounting for 3.60% of the total shares.
ARK Investment Management LLC holds 10.18M shares, accounting for 11.20% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.42M shares, accounting for 5.96% of the total shares.
Capital International Investors holds 5.59M shares, accounting for 6.15% of the total shares.
Orbis Investment Management Ltd. holds 2.76M shares, accounting for 3.04% of the total shares.
State Street Investment Management (US) holds 3.27M shares, accounting for 3.60% of the total shares.
What are the top three shareholder types of CRISPR Therapeutics AG?
The top three shareholder types of CRISPR Therapeutics AG are:
ARK Investment Management LLC
BlackRock Institutional Trust Company, N.A.
Capital International Investors
ARK Investment Management LLC
BlackRock Institutional Trust Company, N.A.
Capital International Investors
How many institutions hold shares of CRISPR Therapeutics AG (CRSP)?
As of 2025Q4, 980 institutions hold shares of CRISPR Therapeutics AG, with a combined market value of approximately 79.52M, accounting for 84.90% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -4.68%.
What is the biggest source of revenue for CRISPR Therapeutics AG?
In --, the -- business generated the highest revenue for CRISPR Therapeutics AG, amounting to -- and accounting for --% of total revenue.
